Evidence map›Paper›PMID 33896121›Full record

ArticleHLA2021

The influence of HLA genotype on the severity of COVID-19 infection.

David J Langton, Stephen C Bourke, Benedicte A Lie, Gabrielle Reiff, Shonali Natu, Rebecca Darlay, John Burn, Carlos Echevarria

Open access · hybridAbstract read
In one paragraph

Article in HLA, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 90 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
90citing papers in PubMed, 3 pooled it
8.1field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

90 citing papers in PubMed, 3 syntheses or guidelines pooled it, 135 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Frontiers in immunology · 2026
    Article
  10. Review
  11. Article
  12. Investigation ofInternational journal of molecular sciences · 2025
    Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Sex-Specific HLA Alleles Contribute to the Modulation of COVID-19 Severity.International journal of molecular sciences · 2024
    Article
  20. Article

30 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 6 institutions in 2 countries.

David J LangtonExplantLab, The Biosphere, Newcastle Helix, Newcastle-upon-Tyne, UK.ORCID 0000-0003-1178-3031
Stephen C BourkeNorthumbria Healthcare NHS Trust, North Tyneside General Hospital, North Shields, Tyne and Wear, UK.
Benedicte A LieDepartment of Medical Genetics, University of Oslo, Oslo, Norway.
Gabrielle ReiffUniversity Hospital of North Tees, Stockton, UK.
Shonali NatuUniversity Hospital of North Tees, Stockton, UK.
Rebecca DarlayNewcastle University Translational and Clinical Research Institute, International Centre for Life (for John Burn) and Population & Health Sciences Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, United Kingdom, for Rebecca Darlay, Newcastle-upon-Tyne, UK.
John BurnNewcastle University Translational and Clinical Research Institute, International Centre for Life (for John Burn) and Population & Health Sciences Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, United Kingdom, for Rebecca Darlay, Newcastle-upon-Tyne, UK.
Carlos EchevarriaTranslational and Clinical Research Institute, Newcastle University and Newcastle Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.
Centre for Life · GBUniversity Hospital of North Tees · GBNewcastle College · GBNewcastle upon Tyne Hospitals NHS Foundation Trust · GBNorth Tyneside General Hospital · GBUniversity of Oslo · NO

Funding

Medical Research Council G0100496
6 · The paper itself

Abstract

The impact of COVID-19 varies markedly, not only between individual patients but also between different populations. We hypothesised that differences in human leukocyte antigen (HLA) genes might influence this variation. Using next generation sequencing, we analysed the class I and class II classical HLA genes of 147 individuals of European descent experiencing variable clinical outcomes following COVID-19 infection. Forty-nine of these patients were admitted to hospital with severe respiratory disease. They had no significant pre-existing comorbidities. We compared the results to those obtained from a group of 69 asymptomatic hospital workers who evidence of COVID exposure based on blood antibody testing. Allele frequencies in both the severe and asymptomatic groups were compared to local and national healthy controls with adjustments made for age and sex. With the inclusion of hospital staff who had reported localised symptoms only (limited to loss of smell/taste, n = 13) or systemic symptoms not requiring hospital treatment (n = 16), we carried out ordinal logistic regression modelling to determine the relative influence of age, BMI, sex and the presence of specific HLA genes on symptomatology. We found a significant difference in the allele frequency of HLA-DRB1*04:01 in the severe patient compared to the asymptomatic staff group (5.1% vs. 16.7%, P = .003 after adjustment for age and sex). There was a significantly lower frequency of the haplotype DQA1*01:01-DQB1*05:01-DRB1*01:01 in the asymptomatic group compared to the background population (P = .007). Ordinal logistic regression modelling confirmed the significant influence of DRB1*04:01 on the clinical severity of COVID-19 observed in the cohorts. These alleles are found in greater frequencies in the North Western European population. This regional study provides evidence that HLA genotype influences clinical outcome in COVID-19 infection. Validation studies must take account of the complex genetic architecture of the immune system across different geographies and ethnicities.

Indexed as

COVID-19AllelesGene FrequencyGenotypeHaplotypesHLA-DQ alpha-ChainsHLA-DQ AntigensHLA-DQ beta-ChainsHLA-DRB1 ChainsHumansSARS-CoV-2HLA-DQ alpha-ChainsHLA-DQ AntigensHLA-DQ beta-ChainsHLA-DRB1 ChainsCOVIDCOVID-19geneticsHLAlatitudevirus

Identifiers

PMID33896121
PMCPMC8251294
OpenAlexW3158049500

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.